Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, and PK Study of an IV Form of TR-701 Free Acid and an Open-Label, Crossover Absolute BA Determination of a TR-701 FA Tablet in Normal Healthy Adults

Next Previous
Trial Profile

A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, and PK Study of an IV Form of TR-701 Free Acid and an Open-Label, Crossover Absolute BA Determination of a TR-701 FA Tablet in Normal Healthy Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tedizolid (Primary) ; Tedizolid (Primary)
  • Indications Gram-positive infections; Skin and soft tissue infections
  • Focus Adverse reactions
  • Acronyms IV/SAD/MAD
  • Sponsors Cubist Pharmaceuticals; Trius Therapeutics

Most Recent Events

  • 12 Sep 2010 Pharmacokinetic results presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
  • 26 Jul 2010 Actual patient number is xx according to ClinicalTrials.gov.
  • 26 Jul 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top